source
- Avalo Therapeutics reports Phase 2 success in inflammatory skin disorder and secures $375M financingAvalo Therapeutics announced on May 6, 2026 that its experimental immunology drug met its primary endpoints in a Phase 2 study of an inflammatory skin condition. The trial tested two dose levels,…
- Avalo's Phase 2 data lifts shares 45% as skin drug shows 42% response in hidradenitis suppurativaAvalo Therapeutics reported that its experimental therapy abdakibart met the primary goal of a Phase 2 trial in patients with hidradenitis suppurativa. Both low and high dose groups achieved respon…